EU Approval Makes ESR1 Emergence Actionable

Company AstraZeneca Event Type Regulatory Approval (European Commission) Modality Oral Selective Estrogen-Receptor Degrader (SERD) Asset Etcamah (Camizestrant) Target Estrogen Receptor Alpha (ESR1, Wild-Type and Mutant) Disease Area ER-Positive, HER2-Negative Advanced Breast Cancer (ESR1-Mutant, Molecular Switch) Summary The European Commission approved AstraZeneca’s Etcamah, or camizestrant, with…